Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...

O n Wednesday, Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at ...

Goldman Sachs analyst Salveen Richter initiated coverage of the company’s stock with a “Buy” rating and a price objective of $42. As per the analyst, Summit Therapeutics Inc. (NASDAQ ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

What Else: Goldman Sachs analyst Salveen Richter recently downgraded Moderna from Buy to Neutral and lowered the price target from $99 to $51, citing lower conviction following a second product ...

Goldman Sachs analyst Salveen Richter notes that Biogen’s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in ...

The company ended the year with $11.2 billion in cash and investments. Salveen Richter, Goldman Sachs: Questioned retail pharmacy and P&T committee pre-launch efforts for JOURNAVX. COO Stuart ...

Salveen Richter; Analyst; Goldman Sachs & Company, Inc. James Shin; Analyst; Deutsche Bank Securities Inc. Greetings and welcome to the Incyte fourth-quarter 2024 and full-year financial and ...

Salveen Richter, Goldman Sachs: Inquired about BLU-808’s safety profile and potential dosing strategies. CMO Becker Hewes noted the drug’s wide therapeutic index and plans to test various ...